Skip to content

Study · Randomized controlled trial · 2023

20 results

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML

The New England journal of medicine26 Jun 2023Cited by 826 (Europe PMC)

PMID37366315 (opens in a new tab)DOI10.1056/nejmoa2301972 (opens in a new tab)PepBankPUB-37366315
Publisher pagePubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 1 mg reduced body weight by 7.2% at 24 weeks, versus 1.6% with placebo.

    In plain wordsIn adults with obesity, retatrutide 1 mg lowered body weight more than placebo at 24 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 24 weeks, 1 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −7.2%
    1 mg, week 24

    Source sentences

    Summary
    The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group.
    3 context sentences
    Summary · context
    The primary end point was the percentage change in body weight from baseline to 24 weeks.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 4 mg reduced body weight by 12.9% at 24 weeks, versus 1.6% with placebo.

    In plain wordsIn adults with obesity, retatrutide 4 mg lowered body weight more than placebo at 24 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 24 weeks, 4 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly (combined 4-mg group) · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −12.9%
    combined 4 mg, week 24

    Source sentences

    Summary
    The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group.
    3 context sentences
    Summary · context
    The primary end point was the percentage change in body weight from baseline to 24 weeks.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 8 mg reduced body weight by 17.3% at 24 weeks, versus 1.6% with placebo.

    In plain wordsIn adults with obesity, retatrutide 8 mg lowered body weight more than placebo at 24 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 24 weeks, 8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    8 mg once weekly (combined 8-mg group) · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −17.3%
    combined 8 mg, week 24

    Source sentences

    Summary
    The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group.
    3 context sentences
    Summary · context
    The primary end point was the percentage change in body weight from baseline to 24 weeks.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 12 mg reduced body weight by 17.5% at 24 weeks, versus 1.6% with placebo.

    In plain wordsIn adults with obesity, retatrutide 12 mg lowered body weight more than placebo at 24 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 24 weeks, 12 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −17.5%
    12 mg, week 24

    Source sentences

    Summary
    The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group.
    3 context sentences
    Summary · context
    The primary end point was the percentage change in body weight from baseline to 24 weeks.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 1 mg reduced body weight by 8.7% at 48 weeks, versus 2.1% with placebo.

    In plain wordsIn adults with obesity, retatrutide 1 mg lowered body weight more than placebo at 48 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 48 weeks, 1 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −8.7%
    1 mg, week 48

    Source sentences

    Summary
    At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 4 mg reduced body weight by 17.1% at 48 weeks, versus 2.1% with placebo.

    In plain wordsIn adults with obesity, retatrutide 4 mg lowered body weight more than placebo at 48 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 48 weeks, 4 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly (combined 4-mg group) · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −17.1%
    combined 4 mg, week 48

    Source sentences

    Summary
    At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 8 mg reduced body weight by 22.8% at 48 weeks, versus 2.1% with placebo.

    In plain wordsIn adults with obesity, retatrutide 8 mg lowered body weight more than placebo at 48 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 48 weeks, 8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    8 mg once weekly (combined 8-mg group) · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −22.8%
    combined 8 mg, week 48

    Source sentences

    Summary
    At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, retatrutide 12 mg reduced body weight by 24.2% at 48 weeks, versus 2.1% with placebo.

    In plain wordsIn adults with obesity, retatrutide 12 mg lowered body weight more than placebo at 48 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change at 48 weeks, 12 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Body weight change
    −24.2%
    12 mg, week 48

    Source sentences

    Summary
    At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 92% of those given retatrutide 4 mg had a weight reduction of 5% or more at 48 weeks, versus 27% with placebo.

    In plain wordsIn adults with obesity, 92% on retatrutide 4 mg lost 5% or more of body weight at 48 weeks, versus 27% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 5% or more at 48 weeks, 4 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=5%
    92%
    4 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 75% of those given retatrutide 4 mg had a weight reduction of 10% or more at 48 weeks, versus 9% with placebo.

    In plain wordsIn adults with obesity, 75% on retatrutide 4 mg lost 10% or more of body weight at 48 weeks, versus 9% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 10% or more at 48 weeks, 4 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=10%
    75%
    4 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 60% of those given retatrutide 4 mg had a weight reduction of 15% or more at 48 weeks, versus 2% with placebo.

    In plain wordsIn adults with obesity, 60% on retatrutide 4 mg lost 15% or more of body weight at 48 weeks, versus 2% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 15% or more at 48 weeks, 4 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=15%
    60%
    4 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 100% of those given retatrutide 8 mg had a weight reduction of 5% or more at 48 weeks, versus 27% with placebo.

    In plain wordsIn adults with obesity, 100% on retatrutide 8 mg lost 5% or more of body weight at 48 weeks, versus 27% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 5% or more at 48 weeks, 8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    8 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=5%
    100%
    8 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 91% of those given retatrutide 8 mg had a weight reduction of 10% or more at 48 weeks, versus 9% with placebo.

    In plain wordsIn adults with obesity, 91% on retatrutide 8 mg lost 10% or more of body weight at 48 weeks, versus 9% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 10% or more at 48 weeks, 8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    8 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=10%
    91%
    8 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 75% of those given retatrutide 8 mg had a weight reduction of 15% or more at 48 weeks, versus 2% with placebo.

    In plain wordsIn adults with obesity, 75% on retatrutide 8 mg lost 15% or more of body weight at 48 weeks, versus 2% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 15% or more at 48 weeks, 8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    8 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=15%
    75%
    8 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  15. 15HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 100% of those given retatrutide 12 mg had a weight reduction of 5% or more at 48 weeks, versus 27% with placebo.

    In plain wordsIn adults with obesity, 100% on retatrutide 12 mg lost at least 5% of body weight at 48 weeks, versus 27% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 5% or more at 48 weeks, 12 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=5%
    100%
    12 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  16. 16HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 93% of those given retatrutide 12 mg had a weight reduction of 10% or more at 48 weeks, versus 9% with placebo.

    In plain wordsIn adults with obesity, 93% on retatrutide 12 mg lost 10% or more of body weight at 48 weeks, versus 9% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 10% or more at 48 weeks, 12 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=10%
    93%
    12 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  17. 17HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, 83% of those given retatrutide 12 mg had a weight reduction of 15% or more at 48 weeks, versus 2% with placebo.

    In plain wordsIn adults with obesity, 83% on retatrutide 12 mg lost 15% or more of body weight at 48 weeks, versus 2% on placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseWeight reduction of 15% or more at 48 weeks, 12 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Responders with weight reduction >=15%
    83%
    12 mg, week 48

    Source sentences

    Summary
    At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of tho…
    3 context sentences
    Summary · context
    Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more.
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  18. 18HumanRandomized controlled trialSafety outcome

    In adults with obesity, the most common adverse events with retatrutide were gastrointestinal, dose-related and mostly mild to moderate.

    In plain wordsIn adults with obesity, the most common retatrutide side effects were stomach and gut problems, mostly mild to moderate and dose-related.

    Peptide
    Retatrutide
    Outcome
    Not applicableGastrointestinal adverse events
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1 to 12 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg).
    2 context sentences
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  19. 19HumanRandomized controlled trialSafety outcome

    In adults with obesity, a lower retatrutide starting dose (2 mg versus 4 mg) partially mitigated the gastrointestinal adverse events.

    In plain wordsIn adults with obesity, starting retatrutide at 2 mg rather than 4 mg partly reduced stomach and gut side effects.

    Peptide
    Retatrutide
    Outcome
    DecreaseGastrointestinal events with lower starting dose
    Study

    n: not reported in source

    Comparator
    Starting dose 4 mg
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    starting dose 2 mg · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg).
    2 context sentences
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.
  20. 20HumanRandomized controlled trialSafety outcome

    In adults with obesity, retatrutide caused dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter.

    In plain wordsIn adults with obesity, retatrutide raised heart rate in a dose-dependent way, peaking at 24 weeks and then declining.

    Peptide
    Retatrutide
    Outcome
    IncreaseHeart rate increase
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    dose-dependent · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.
    2 context sentences
    Summary · context
    We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.
    Summary · context
    Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04881760

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Eli Lilly and Companyn = 33820 May 2021 to 22 Nov 2022

Obesity · Overweight

Trial pageClinicalTrials.govUpdated 13 Sept 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.